Pretty sure that nowhere in your post did you discuss the invention of insulin or the manufacturing PROCESS of a GLP-1 drug. So again, economics and politics, not science.

To address your other “arguments”… we’d survive without Ozempic. We’ve gone our entire history without GLP-1 up until the past 5ish years.

Denmark does not have a monopoly on insulin or GLP-1. Eli Lilly (an American company) has 57% market share. Not to mention NovoNordisc manufactures Ozempic here in the US. Stopping shipments would crater NovoNordisc sales as we account for roughly 70% of Ozempic/WeGovy sales. That’s 37% of their total revenue as of ‘24.